


The background features a light gray gradient with several overlapping geometric shapes. A large, light gray diamond is centered, with a smaller, darker gray diamond to its left. A white diamond is also present, overlapping the light gray one. Faint, semi-transparent circles are scattered in the background.

Head and Neck Cancers

《 Cancer of the oral cavity-1 》

Work-Ups Clinical Staging Primary Treatment Pathological(first)/Image Finding Adjuvant Treatment Follow-Up



*1 Pathologic risk factors: surgical margin with residual tumor, ECS(+), N2 or N3 node disease, pT3 or pT4 primary, node disease in Level IV or V、PNI(note)、LVI、Type V-WPOI

*2 no pathologic risk factor: T1-T2, N1 → OBS or RT note: PNI alone in early stage (stage I、II) selective treatment

*3 consider re-resection to achieve negative margins for positive resection margins if feasible

* Pathological(first)/Image Finding

《 Cancer of the oral cavity-2 》

Work-Ups


Clinical Staging

Primary Treatment

Pathological(first)/Image Finding

Adjuvant Treatment

Follow-Up



* Pathological(first)/Image Finding

《 Oral cavity 》

Work-Up

Necessary examination

- Biopsy
- Chest radiography
- H&N MRI or CT
- Whole body bone scan (optional if early stage)
- Abdomen sonography
- Dental consultation (prior to R/T)
- Dietician consultation
- Speech & swallowing evaluation)
- ENT consultation

Optional examination

- Screening for hepatitis B
- PET-CT for stage III-IV disease
- Panendoscopy (if smoking or drinking wine)

《 Cancer of the Hypopharynx -1 》

Work-Up

Clinical Staging

Primary Treatment

Pathological(first)/
Image Finding

Adjuvant
Treatment

Follow-Up

Necessary examination

- Biopsy
- Laryngoscopy
- Chest radiography
- H&N MRI or CT
- Whole body bone scan (optional if early stage)
- Abdomen sonography
- Panendoscopy(if smoking or drinking alcohol)
- Dental consultation (prior to R/T)
- Dietician consultation
- Speech & swallowing evaluation

Optional examination

- PET-CT for stage III-IV disease
- Bronchoscopy
- Audiometry
- Pulmonary function test(advanced T status is indicated)

Screening for hepatitis B

T1-2 , N0-3
(adequate
Laryngeal
function)

Organ
preservation
treatment

RT or CCRT or bio-RT or
induction C/T + RT or
induction C/T + CCRT

Primary and
neck controlled

Residual
tumor*

Salvage surgery

Salvage C/T or
supportive care
or clinical trails

see Follow-Up

Partial
laryngopharyngecto
my+ipsilateral or
bil ateral selective
neck dissection±
hemithyroidectomy

No pathologic risk
factors

With pathologic
risk factors¹

re-resection for positive
margins² or RT or CCRT or
bio-RT


Elective neck dissection for Large($\geq 6\text{cm}$) ± central necrosis(N2 or N3) of LAP followed by Definitive CCRT or bio-RT)

* 1 Extranodal extension, positive margins, close margins, pT3 or pT4 primary, pN2 or pN3 nodal disease, nodal disease in levels IV or V, perineural invasion, lymphovascular invasion

* 2 consider re-resection to achieve negative margins for positive resection margins if feasible

* Pathological(first)/Image Finding

《 Cancer of the Hypopharynx -2 》




Elective neck dissection for Large ($\geq 6\text{cm}$) \pm central necrosis(N2 or N3) of LAP followed by Definitive CCRT or bio-RT)

* 1 Extranodal extension, positive margins, close margins, pT3 or pT4 primary, pN2 or pN3 nodal disease, nodal disease in levels IV or V, perineural invasion, lymphovascular invasion

* 2 consider re-resection to achieve negative margins for positive resection margins if feasible

* Pathological(first)/Image Finding

《 Cancer of the Hypopharynx -3 》




Elective neck dissection for Large ($\geq 6\text{cm}$) \pm central necrosis(N2 or N3) of LAP followed by Definitive CCRT or bio-RT)

* 1 Extranodal extension, positive margins, close margins, pT3 or pT4 primary, pN2 or pN3 nodal disease, nodal disease in levels IV or V, perineural invasion, lymphovascular invasion

* 2 consider re-resection to achieve negative margins for positive resection margins if feasible

* Pathological(first)/Image Finding

《 Cancer of the Oropharynx -1 》




Elective neck dissection for Large ($\geq 6\text{cm}$) ± central necrosis(N2 or N3) of LAP followed by Definitive CCRT or bio-RT)

* 1 Extranodal extension, positive margins, close margins, pT3 or pT4 primary, pN2 or pN3 nodal disease, nodal disease in levels IV or V, perineural invasion, lymphovascular invasion

* 2 consider re-resection to achieve negative margins for positive resection margins if feasible

* Pathological(first)/Image Finding

《 Cancer of the Oropharynx -2 》



Elective neck dissection for Large ($\geq 6\text{cm}$) ± central necrosis(N2 or N3) of LAP followed by Definitive CCRT or bio-RT)

* 1 Extranodal extension, positive margins, close margins, pT3 or pT4 primary, pN2 or pN3 nodal disease, nodal disease in levels IV or V, perineural invasion, lymphovascular invasion

* 2 consider re-resection to achieve negative margins for positive resection margins if feasible

* Pathological(first)/Image Finding

Work-Up

Clinical Staging


Primary treatment

Pathological(first)/Image Finding

Adjuvant Treatment

Follow-Up

- Necessary examination**
- Biopsy
 - Laryngoscopy
 - Chest radiography
 - H&N MRI or CT
 - Whole body bone scan (optional if early stage)
 - Abdomen sonography
 - Panendoscopy(if smoking or drinking wine)
 - Dental consultation (prior to R/T, except for patients with cT1-T2,N0))
 - Dietician consultation
 - Speech & swallowing evaluation
- Optional examination**
- PET-CT for stage III-IV disease
 - Bronchoscopy
 - Panendoscopy(if smoking or drinking wine)
 - Audiometry
 - Pulmonary function test(advanced T status is indicated)
 - Screening for hepatitis B




Elective neck dissection for Large ($\geq 6\text{cm}$) \pm central necrosis(N2 or N3) of LAP followed by Definitive CCRT or bio-RT

* 1 Extranodal extension, positive margins, close margins, pT3 or pT4 primary, pN2 or pN3 nodal disease, nodal disease in levels IV or V, perineural invasion, lymphovascular invasion

* 2 consider re-resection to achieve negative margins for positive resection margins if feasible

* Pathological(first)/Image Finding

《 Cancer of the Glottic Larynx -2 》




Elective neck dissection for Large ($\geq 6\text{cm}$) \pm central necrosis(N2 or N3) of LAP followed by Definitive CCRT or bio-RT)

* 1 Extranodal extension, positive margins, close margins, pT3 or pT4 primary, pN2 or pN3 nodal disease, nodal disease in levels IV or V, perineural invasion, lymphovascular invasion

* 2 consider re-resection to achieve negative margins for positive resection margins if feasible

* Pathological(first)/Image Finding

《 Cancer of the Glottic Larynx -3 》




Elective neck dissection for Large ($\geq 6\text{cm}$) \pm central necrosis (N2 or N3) of LAP followed by Definitive CCRT or bio-RT)

* 1 Extranodal extension, positive margins, close margins, pT3 or pT4 primary, pN2 or pN3 nodal disease, nodal disease in levels IV or V, perineural invasion, lymphovascular invasion *

* 2 consider re-resection to achieve negative margins for positive resection margins if feasible

*Pathological(first)/Image Finding

《 Cancer of the Nasopharynx -1 》



《 follow up recommendation 》

Follow-up frequency

- Every month in the 1st year after treatment
- Every 2-3 months in the 2nd year after treatment
- Every 3 months in the 3rd year after treatment
- Every 6 months in the 4th-5th year after treatment

H&N MRI or CT

- Every 3-6 months within the first 3 years after treatment
- Every 6-12 months beyond 3 years after treatment

Whole body bone scan

- Every 3-6 months within the first 3 years after treatment
- Every 6-12 months beyond 3 years after treatment

Abdomen sonography

- Every 3-6 months within the first 3 years after treatment
- Every 6-12 months beyond 3 years after treatment

PET and Whole body bone scan and Panendoscopy

- If indicated clinically

《 Reference 》

1. Al-Sarrf M, LeBlanc M, Giri PG, et al. Chemotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer : phase III randomized Intergroup study 0099. *J Clin Oncol* 1998; 16:1310-1317. Wee J, Tan EH, Tai BC, et al. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union against cancer stage III and IV nasopharyngeal cancer of the endemic variety. *J Clin Oncol* 2005; 23 : 6730-6738.
2. NCCN Head abd Neck Cancer Guidelines Version 5,2024
3. Bernier J, Domezge C, Ozsahin M et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. *N Engl J Med* 2004; 350:1945-1952.
4. Budach W, Hehr T, Budach V, et al. A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck. *BMC Cancer* 2006; 6 : 28-38.
5. Chan AT, Leung SF, Ngan RK, et al. Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma. *J Natl Cancer Inst* 2005; 97: 536-539.
6. Chan ATC, Hsu M-M, Goh BC, et al. Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. *J Clin Oncol* 2005; 23: 3568-3576.
7. Cooper JS, Pajak TF, Forastiere AA et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. *N Engl J Med* 2004; 350(19) : 1937-1944.
8. Hartford AC, Palosca MG, Eichler TJ, et al. American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) Practice Guidelines for Intensity-Modulated Radiation Therapy (IMRT). *Int J Radiat Oncol Biol Phys* 2009; 73: 9-14.

